Edwards Soars After Raising Forecast for Third Time in a Row

Updated on
  • Adjusted earnings of 76 cents a share top 70-cent estimate
  • Boosts annual profit forecast to range of $2.78 to $2.88

Edwards Lifesciences Corp. soared after the world’s largest maker of aortic valves implanted without open-heart surgery beat analysts’ estimates and raised its 2016 earnings forecast for a third quarter in a row as younger and healthier patients started getting the devices.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.